HIV Incidence and Participation Retention in Pune, India

NCT ID: NCT00028119

Last Updated: 2022-08-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1070 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-08-31

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to ensure that the HIV Prevention Trials Unit (HPTU) in Pune will be able to enroll and retain participants for 2 upcoming HPTN clinical trials. Specifically, this study seeks to find the rate of HIV infection and follow-up among a group of high-risk, HIV-negative non-sexworker women in Pune, as well as among HIV-discordant couples (couples where 1 partner is HIV-infected and the other is not).

Phase III studies of HIV prevention require the participation of a large number of people at high risk for HIV infection. It is also important that these participants continue and follow through with the study through the extended period of follow-up. A measurement of HIV incidence and retention rate among high-risk women and HIV-discordant couples is necessary for upcoming HPTN trials. Taken together with the need for estimates of HIV incidence and the need for data to ensure high retention rates, this protocol is important for the HPTN generally and for HPTU in Pune in particular.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Previous prevention-trial planning efforts have indicated that Phase III studies of HIV prevention interventions will require the participation of large numbers of persons at high risk for HIV infection. In addition to accruing large numbers of participants, research centers conducting Phase III HIV prevention studies must retain participants in extended periods of follow-up in order to accurately reflect the impact of the intervention in the target population. A current measurement of HIV incidence, the risk factors associated with HIV infection, and the retention rate of newly enrolled high-risk women is necessary for an upcoming HPTN trial. In addition, HPTN requires an assessment of its ability to enroll and retain HIV-discordant couples for a proposed HPTN trial, as well as a timely assessment of the HIV incidence rate in these exposed partners. This study will provide essential experience and a preliminary base for the enrollment of discordant couples into future HPTN clinical trials. Taken together with the need for current estimates of HIV incidence in the cohort and community populations and the need for data to ensure high retention rates, this protocol is important for the HPTN generally and for HPTU in Pune in particular.

Potential study participants will undergo eligibility screening, including administration of a questionnaire, physical examination, and HIV antibody testing. Once participants are enrolled in the study, the requirements will include follow-up every 3 months for 17.5 months, phlebotomy, physical exams, and questionnaires. At every follow-up visit, a short questionnaire will be administered to all participants to assess their continued understanding about the nature, duration, benefits and risks of being in the study and to assure their voluntary participation in the study. Participants seen in follow-up also will have a physical examination, be evaluated and treated for any STDs, receive additional counseling, and be offered retesting for HIV infection. In addition, participants also will be invited to participate in additional assessment issues addressing retention using a series of focus groups, key informant interviews, and individual qualitative and quantitative assessments. Participants in this protocol may also be eligible to enroll into 1 of 2 proposed ancillary laboratory substudies (HPTN 034A and 034B).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections HIV Seronegativity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

HIV-uninfected non-sex worker women

No interventions assigned to this group

Cohort 2

HIV-discordant heterosexual couples attending STD clinics

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

HIV-uninfected women may be eligible if they are:

* At least 18 years old.
* Able and willing to provide written informed consent for HIV testing and to take part in this study.
* Willing to receive their HIV test results.
* HIV-negative.
* Available for at least 17.5 months of study follow-up.

HIV-infected partners (index partner) in the HIV-discordant couples may be eligible if they are:

* At least 18 years old.
* Able and willing to provide written consent for HIV testing and to take part in this study.
* Willing to receive their HIV test results.
* HIV-positive.
* Available for at least 17.5 months of study follow-up.
* Presently in a sexual relationship with the same partner for at least 3 months.
* Intending to remain with this partner for the duration of the study.
* Willing to identify his/her sexual partner and disclose his/her HIV status to partner.
* Willing to attempt to recruit their partner.

Partners of HIV-infected index partners in the HIV-discordant couples may be eligible if they are:

* At least 18 years old.
* Able and willing to provide written consent for HIV testing.
* Willing to receive their HIV test results.
* HIV-negative.

HIV-discordant couples may be eligible if they first meet the criteria in 2 and 3 above and also if:

* Each partner agrees to participate in the study together.
* Each partner is able and willing to provide written informed consent to take part in the study.
* The partners have been in a sexual relationship for at least the prior 3 months.
* Each partner is available for at least 17.5 months of study follow-up.
* Each couple has stated intention to continue their relationship for at least 17.5 months.
* Each partner is willing and able to attend each scheduled follow-up study visit.

Exclusion Criteria

Persons may not be eligible for this study if they:

* Are HIV-uninfected women who report a history of prior commercial sex work. However, HIV-infected female commercial sex workers can be enrolled in the HIV-discordant partners study with their HIV-uninfected male sexual partner.
* Have mental problems that would interfere with study participation.
* Have any other condition that, in the opinion of the investigator, would interfere with the study.
* Are an HIV-discordant couple that reports a history of domestic violence.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

HIV Prevention Trials Network

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Bollinger

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Sanjay Mehendale

Role: PRINCIPAL_INVESTIGATOR

NARI Pune CRS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National AIDS Research Institute

Pune, , India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U01AI046749

Identifier Type: NIH

Identifier Source: secondary_id

View Link

HPTN 034B substudy

Identifier Type: -

Identifier Source: secondary_id

HPTN 034A substudy

Identifier Type: -

Identifier Source: secondary_id

HPTN 034

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.